Accrued Liabilities, Current of Protalix BioTherapeutics, Inc. from 31 Dec 2011 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Summary
Protalix BioTherapeutics, Inc. quarterly Accrued Liabilities, Current in USD history and change rate from 31 Dec 2011 to 30 Sep 2025.
  • Protalix BioTherapeutics, Inc. Accrued Liabilities, Current for the quarter ending 30 Sep 2025 was $8,126,000, a 2.6% decline year-over-year.
Source SEC data
View on sec.gov
Accrued Liabilities, Current, Quarterly (USD)
Accrued Liabilities, Current, YoY Quarterly Change (%)

Protalix BioTherapeutics, Inc. Quarterly Accrued Liabilities, Current (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $8,126,000 -$216,000 -2.6% 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $7,311,000 -$2,076,000 -22% 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $9,349,000 +$898,000 +11% 31 Mar 2025 10-Q 09 May 2025 2025 Q1
Q4 2024 $9,568,000 +$559,000 +6.2% 31 Dec 2024 10-Q 13 Nov 2025 2025 Q3
Q3 2024 $8,342,000 -$907,000 -9.8% 30 Sep 2024 10-Q 14 Nov 2024 2024 Q3
Q2 2024 $9,387,000 +$779,000 +9% 30 Jun 2024 10-Q 14 Aug 2024 2024 Q2
Q1 2024 $8,451,000 31 Mar 2024 10-Q 10 May 2024 2024 Q1
Q4 2023 $9,009,000 +$1,531,000 +20% 31 Dec 2023 10-K 17 Mar 2025 2024 FY
Q3 2023 $9,249,000 30 Sep 2023 10-Q 06 Nov 2023 2023 Q3
Q2 2023 $8,608,000 30 Jun 2023 10-Q 07 Aug 2023 2023 Q2
Q4 2022 $7,478,000 -$4,503,000 -38% 31 Dec 2022 10-K 14 Mar 2024 2023 FY
Q4 2021 $11,981,000 +$2,395,000 +25% 31 Dec 2021 10-K 27 Feb 2023 2022 FY
Q4 2020 $9,586,000 +$2,226,000 +30% 31 Dec 2020 10-K 31 Mar 2022 2021 FY
Q4 2019 $7,360,000 +$992,000 +16% 31 Dec 2019 10-K 30 Mar 2021 2020 FY
Q4 2018 $6,368,000 +$1,566,000 +33% 31 Dec 2018 10-K 12 Mar 2020 2019 FY
Q4 2017 $4,802,000 +$1,227,000 +34% 31 Dec 2017 10-K 18 Mar 2019 2018 FY
Q4 2016 $3,575,000 +$2,004,000 +128% 31 Dec 2016 10-K 06 Mar 2018 2017 FY
Q4 2015 $1,571,000 -$1,542,000 -50% 31 Dec 2015 10-K 16 Mar 2017 2016 FY
Q4 2014 $3,113,000 +$1,328,000 +74% 31 Dec 2014 10-K 08 Mar 2016 2015 FY
Q4 2013 $1,785,000 -$247,000 -12% 31 Dec 2013 10-K 12 Mar 2015 2014 FY
Q4 2012 $2,032,000 -$295,000 -13% 31 Dec 2012 10-K 13 Mar 2014 2013 FY
Q4 2011 $2,327,000 31 Dec 2011 10-K 28 Feb 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.